{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T15:27:23Z","timestamp":1793114843233,"version":"4.5.0"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,21]],"date-time":"2025-01-21T00:00:00Z","timestamp":1737417600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Global Antimicrobial Resistance"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.jgar.2025.01.007","type":"journal-article","created":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T12:24:12Z","timestamp":1737980652000},"page":"272-279","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"special_numbering":"C","title":["Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane\/Tazobactam Real-world Analysis (SPECTRA)"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9374-0811","authenticated-orcid":false,"given":"Alex","family":"Soriano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David L.","family":"Paterson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Thalhammer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Kluge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierluigi","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre H.","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mike","family":"Allen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brune","family":"Akrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Wirbel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1807-3465","authenticated-orcid":false,"given":"Engels N.","family":"Obi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6036-9526","authenticated-orcid":false,"given":"Emre","family":"Y\u00fccel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Kaul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jgar.2025.01.007_bib0001","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1306801","article-title":"for the Emerging Infections Program Healthcare-Associated Infections and Antimicrobial Use Prevalence Survey Team. Multistate point-prevalence survey of health care-associated infections","volume":"370","author":"Magill","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.01.007_bib0002","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/cit254","article-title":"Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implication for hospitals","volume":"57","author":"Shorr","year":"2013","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0003","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.suc.2011.11.003","article-title":"Hospital-acquired infections","volume":"92","author":"Lobdell","year":"2012","journal-title":"Surg Clin North Am"},{"key":"10.1016\/j.jgar.2025.01.007_bib0004","series-title":"Pharmacotherapy Self-Assessment Program","first-page":"235","article-title":"Nosocomial gram-negative infections","author":"Martin","year":"2005"},{"key":"10.1016\/j.jgar.2025.01.007_bib0005","unstructured":"Centers for Disease Control and Prevention. HAI pathogens and antimicrobial resistance report, 2018\u20132021. Published 2023. Accessed 3 November 2023. https:\/\/www.cdc.gov\/nhsn\/hai-report\/index.html."},{"key":"10.1016\/j.jgar.2025.01.007_bib0006","doi-asserted-by":"crossref","first-page":"1804","DOI":"10.1056\/NEJMra0904124","article-title":"Hospital-acquired infections due to gram-negative bacteria","volume":"362","author":"Peleg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jgar.2025.01.007_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1017\/ice.2019.296","article-title":"Antimicrobial-resistant pathogens associated with adult healthcare-associated infections: summary of data reported to the National Healthcare Safety Network, 2015-2017","volume":"41","author":"Weiner-Lastinger","year":"2020","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2025.01.007_bib0008","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.jiph.2019.02.014","article-title":"Factors influencing mortality in hospital-acquired pneumonia caused by Gram-negative bacteria in China","volume":"12","author":"Feng","year":"2019","journal-title":"J Infect Public Health"},{"key":"10.1016\/j.jgar.2025.01.007_bib0009","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.ijid.2015.06.024","article-title":"Nosocomial Gram-negative bacteremia in intensive care: epidemiology, antimicrobial susceptibilities, and outcomes","volume":"37","author":"Sligl","year":"2015","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0010","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1016\/S1473-3099(19)30403-7","article-title":"Ceftolozane\u2013tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial","volume":"19","author":"Kollef","year":"2019","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0011","doi-asserted-by":"crossref","first-page":"761","DOI":"10.2147\/IDR.S236026","article-title":"Contributing factors to the clinical and economic burden of patients with laboratory-confirmed carbapenem-nonsusceptible gram-negative respiratory infections","volume":"13","author":"McCann","year":"2020","journal-title":"Infect Drug Resist"},{"key":"10.1016\/j.jgar.2025.01.007_bib0012","doi-asserted-by":"crossref","first-page":"e01350","DOI":"10.1128\/AAC.01350-17","article-title":"In vitro comparison of ceftolozane-tazobactam to traditional beta-lactams and ceftolozane-tazobactam as an alternative to combination antimicrobial therapy for Pseudomonas aeruginosa","volume":"61","author":"Goodlet","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.01.007_bib0013","doi-asserted-by":"crossref","first-page":"e02564","DOI":"10.1128\/AAC.02564-18","article-title":"A combination antibiogram evaluation for Pseudomonas aeruginosa in respiratory and blood sources from intensive care unit (ICU) and non-ICU settings in U.S. hospitals","volume":"63","author":"Puzniak","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jgar.2025.01.007_bib0014","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41585-020-0362-4","article-title":"Epidemiology, definition and treatment of complicated urinary tract infections","volume":"17","author":"Wagenlehner","year":"2020","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.jgar.2025.01.007_bib0015","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1186\/s12879-021-06229-x","article-title":"Burden of illness in US hospitals due to carbapenem-resistant Gram-negative urinary tract infections in patients with or without bacteraemia","volume":"21","author":"Shields","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0229393","article-title":"Attributable burden in patients with carbapenem-nonsusceptible gram-negative respiratory infections","volume":"15","author":"Tabak","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jgar.2025.01.007_bib0017","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.annemergmed.2020.08.022","article-title":"Emergence of extended-spectrum \u03b2-lactamase urinary tract infections among hospitalized emergency department patients in the United States","volume":"77","author":"Talan","year":"2021","journal-title":"Ann Emerg Med"},{"key":"10.1016\/j.jgar.2025.01.007_bib0018","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1093\/cid\/cix411","article-title":"Impact on morbidity, mortality, and length of stay of hospital-acquired infections by resistant microorganisms","volume":"65","author":"Barrasa-Villar","year":"2017","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0019","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.2146\/ajhp150049","article-title":"Ceftolozane\u2013tazobactam: a new-generation cephalosporin","volume":"72","author":"Cluck","year":"2015","journal-title":"Am J Health Syst Pharm"},{"key":"10.1016\/j.jgar.2025.01.007_bib0020","doi-asserted-by":"crossref","first-page":"1462","DOI":"10.1093\/cid\/civ097","article-title":"Ceftolozane\/tazobactam plus metronidazole for complicated intra-abdominal infections in an era of multidrug resistance: results from a randomized, double-blind, phase 3 trial (ASPECT-cIAI)","volume":"60","author":"Solomkin","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0021","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(14)62220-0","article-title":"Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)","volume":"385","author":"Wagenlehner","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jgar.2025.01.007_bib0022","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1001\/archsurg.2011.41","article-title":"Increases in mortality, length of stay, and cost associated with hospital-acquired infections in trauma patients","volume":"146","author":"Glance","year":"2011","journal-title":"Arch Surg"},{"key":"10.1016\/j.jgar.2025.01.007_bib0023","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s13756-020-00871-x","article-title":"Infections and antimicrobial resistance in intensive care units in lower-middle income countries: a scoping review","volume":"10","author":"Saharman","year":"2021","journal-title":"Antimicro Resist Infect Control"},{"key":"10.1016\/j.jgar.2025.01.007_bib0024","unstructured":"International Society for Pharmacoepidemiology (ISPE). Guidelines for good pharmacoepidemiology practices (GPP). Revised June 2015. Accessed 12 April 2024. https:\/\/www.pharmacoepi.org\/resources\/guidelines_08027.cfm."},{"key":"10.1016\/j.jgar.2025.01.007_bib0025","unstructured":"Word Medical Association. Declaration of Helsinki. October 2013. Accessed 12 April 2024. http:\/\/www.wma.net\/."},{"key":"10.1016\/j.jgar.2025.01.007_bib0026","unstructured":"European Medicines Agency. Guideline on good pharmacovigilance practices (GVP): module VI \u2013 Collection, management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). Effective date 22 November 2017: EMA\/873138\/2011. Accessed 12 April 2024. https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-and-submission-reports-suspected-adverse-reactions-medicinal-products-rev-2_en.pdf."},{"key":"10.1016\/j.jgar.2025.01.007_bib0027","unstructured":"European Parliament and Council. EU General Data Protection Regulation - Regulation (EU) 2016\/679. 27 April 2016. Accessed 12 April 2024. http:\/\/data.europa.eu\/eli\/reg\/2016\/679\/2016-05-04."},{"key":"10.1016\/j.jgar.2025.01.007_bib0028","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1007\/s40121-021-00436-4","article-title":"Cost effectiveness of ceftolozane\/tazobactam compared with meropenem for the treatment of patients with ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia","volume":"10","author":"Naik","year":"2021","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.jgar.2025.01.007_bib0029","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1186\/s13756-021-00933-8","article-title":"Real-world use of ceftolozane\/tazobactam: a systematic literature review","volume":"10","author":"Puzniak","year":"2021","journal-title":"Antimicrob Resist Infect Control"},{"key":"10.1016\/j.jgar.2025.01.007_bib0030","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1186\/s12866-021-02135-z","article-title":"Activity of ceftolozane\/tazobactam against Gram-negative isolates from patients with lower respiratory tract infections \u2013 SMART United States 2018\u20132019","volume":"21","author":"Karlowsky","year":"2021","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.jgar.2025.01.007_bib0031","unstructured":"Centers for Disease Control and Prevention. Antimicrobial resistance & patient safety portal. Published 2023. Accessed 20 April 2023. https:\/\/arpsp.cdc.gov\/profile\/antibiotic-resistance?tab=antibiotic-resistance."},{"key":"10.1016\/j.jgar.2025.01.007_bib0032","doi-asserted-by":"crossref","DOI":"10.1016\/j.diagmicrobio.2020.115172","article-title":"Epidemiology and regional variation of nonsusceptible and multidrug-resistant Pseudomonas aeruginosa isolates from intensive versus non-intensive care units across multiple centers in the United States","volume":"99","author":"Puzniak","year":"2021","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0033","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12879-015-1123-5","article-title":"Appropriate initial antibiotic therapy in hospitalized patients with gram-negative infections: systematic review and meta-analysis","volume":"15","author":"Raman","year":"2015","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0034","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1017\/ice.2021.464","article-title":"Microbiology, empiric therapy and its impact on the outcomes of nonventilated hospital-acquired, ventilated hospital-acquired, and ventilator-associated bacterial pneumonia in the United States, 2014\u20132019","volume":"43","author":"Zilberberg","year":"2022","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.jgar.2025.01.007_bib0035","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12879-017-2383-z","article-title":"Carbapenem resistance, inappropriate empiric treatment and outcomes among patients hospitalized with Enterobacteriaceae urinary tract infection, pneumonia and sepsis","volume":"17","author":"Zilberberg","year":"2017","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0036","series-title":"28th European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Real-world evaluation of ceftolozane\/tazobactam (C\/T) in severely ill patients with sepsis and\/or bacteraemia","author":"Jayakumar","year":"2018"},{"key":"10.1016\/j.jgar.2025.01.007_bib0037","doi-asserted-by":"crossref","first-page":"S296","DOI":"10.1093\/ofid\/ofx163.682","article-title":"Real-world evaluation of ceftolozane\/tazobactam (C\/T) use and clinical outcomes at an Academic Medical Center in Las Vegas","volume":"4","author":"Leuthner","year":"2017","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0038","doi-asserted-by":"crossref","first-page":"ofaa139","DOI":"10.1093\/ofid\/ofaa139","article-title":"Ceftolozane\/tazobactam for treatment of severe ESBL-producing Enterobacterales infections: a multicenter nationwide clinical experience (CEFTABUSE II Study)","volume":"7","author":"Bassetti","year":"2020","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0039","doi-asserted-by":"crossref","first-page":"640","DOI":"10.3390\/antibiotics9100640","article-title":"Ceftolozane\/tazobactam and ceftazidime\/avibactam for multidrug-resistant gram-negative infections in immunocompetent patients: a single-center retrospective study","volume":"9","author":"Cultrera","year":"2020","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.jgar.2025.01.007_bib0040","doi-asserted-by":"crossref","first-page":"ofy280","DOI":"10.1093\/ofid\/ofy280","article-title":"Ceftolozane-tazobactam for the treatment of multidrug-resistant Pseudomonas aeruginosa infections: a multicenter sudy","volume":"5","author":"Gallagher","year":"2018","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0041","series-title":"28th European Congress of Clinical Microbiology and Infectious Diseases","article-title":"Multicentre evaluation of ceftolozane-tazobactam for multidrug-resistant Pseudomonas aeruginosa infections","author":"Jorgensen","year":"2018"},{"key":"10.1016\/j.jgar.2025.01.007_bib0042","doi-asserted-by":"crossref","first-page":"S19","DOI":"10.1016\/j.jval.2021.11.085","article-title":"POSA11 Ceftolozane-tazobactam for the treatment of complicated infections in hospital settings - results from a French real-world study","volume":"25","author":"Ruimy","year":"2022","journal-title":"Value Health"},{"key":"10.1016\/j.jgar.2025.01.007_bib0043","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/j.ijantimicag.2018.11.001","article-title":"for the CEFTABUSE Study Group. Ceftolozane\/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience","volume":"53","author":"Bassetti","year":"2019","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.jgar.2025.01.007_bib0044","doi-asserted-by":"crossref","first-page":"ofad173","DOI":"10.1093\/ofid\/ofad173","article-title":"A real-world multicenter outpatient experience of ceftolozane\/tazobactam","volume":"10","author":"Van Anglen","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jgar.2025.01.007_bib0045","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1001\/jama.2016.0287","article-title":"The third international consensus definitions for sepsis and septic shock (sepsis-3)","volume":"315","author":"Singer","year":"2016","journal-title":"JAMA"}],"container-title":["Journal of Global Antimicrobial Resistance"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525000165?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213716525000165?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T13:09:48Z","timestamp":1741352988000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213716525000165"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":45,"alternative-id":["S2213716525000165"],"URL":"https:\/\/doi.org\/10.1016\/j.jgar.2025.01.007","relation":{},"ISSN":["2213-7165"],"issn-type":[{"value":"2213-7165","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Unveiling results and insights from multinational, multicenter Study of Prescribing patterns and Effectiveness of Ceftolozane\/Tazobactam Real-world Analysis (SPECTRA)","name":"articletitle","label":"Article Title"},{"value":"Journal of Global Antimicrobial Resistance","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jgar.2025.01.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. and The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}